nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—thyroid cancer—thymus cancer	0.786	1	CtDrD
Vandetanib—Appendicitis—Octreotide—thymus cancer	0.00804	0.127	CcSEcCtD
Vandetanib—RET—parathyroid gland—thymus cancer	0.00247	0.0297	CbGeAlD
Vandetanib—Cholecystitis—Octreotide—thymus cancer	0.00216	0.0343	CcSEcCtD
Vandetanib—Cholelithiasis—Octreotide—thymus cancer	0.002	0.0317	CcSEcCtD
Vandetanib—Hypothyroidism—Octreotide—thymus cancer	0.00194	0.0307	CcSEcCtD
Vandetanib—Nail disorder—Octreotide—thymus cancer	0.00192	0.0304	CcSEcCtD
Vandetanib—Nephrolithiasis—Octreotide—thymus cancer	0.00155	0.0245	CcSEcCtD
Vandetanib—Endocrine disorder—Octreotide—thymus cancer	0.0015	0.0238	CcSEcCtD
Vandetanib—Acne—Octreotide—thymus cancer	0.00148	0.0234	CcSEcCtD
Vandetanib—Cellulitis—Octreotide—thymus cancer	0.00137	0.0217	CcSEcCtD
Vandetanib—Cystitis noninfective—Octreotide—thymus cancer	0.00121	0.0192	CcSEcCtD
Vandetanib—Cystitis—Octreotide—thymus cancer	0.0012	0.019	CcSEcCtD
Vandetanib—Bladder pain—Octreotide—thymus cancer	0.00112	0.0178	CcSEcCtD
Vandetanib—BLK—hematopoietic system—thymus cancer	0.00111	0.0134	CbGeAlD
Vandetanib—PTK6—hematopoietic system—thymus cancer	0.00106	0.0127	CbGeAlD
Vandetanib—Gastroenteritis—Octreotide—thymus cancer	0.00102	0.0161	CcSEcCtD
Vandetanib—Hypoglycaemia—Octreotide—thymus cancer	0.000925	0.0147	CcSEcCtD
Vandetanib—Gastrointestinal haemorrhage—Octreotide—thymus cancer	0.000902	0.0143	CcSEcCtD
Vandetanib—PLK4—hematopoietic system—thymus cancer	0.00087	0.0105	CbGeAlD
Vandetanib—Dehydration—Octreotide—thymus cancer	0.000839	0.0133	CcSEcCtD
Vandetanib—Dry skin—Octreotide—thymus cancer	0.000827	0.0131	CcSEcCtD
Vandetanib—TYRO3—hematopoietic system—thymus cancer	0.000817	0.00984	CbGeAlD
Vandetanib—LYN—hematopoietic system—thymus cancer	0.000813	0.00978	CbGeAlD
Vandetanib—Nasopharyngitis—Octreotide—thymus cancer	0.000807	0.0128	CcSEcCtD
Vandetanib—Gastritis—Octreotide—thymus cancer	0.000798	0.0127	CcSEcCtD
Vandetanib—BLK—lymphoid tissue—thymus cancer	0.000784	0.00944	CbGeAlD
Vandetanib—Influenza—Octreotide—thymus cancer	0.00078	0.0124	CcSEcCtD
Vandetanib—Bronchospasm—Octreotide—thymus cancer	0.000767	0.0122	CcSEcCtD
Vandetanib—Pancreatitis—Octreotide—thymus cancer	0.000765	0.0121	CcSEcCtD
Vandetanib—Bronchitis—Octreotide—thymus cancer	0.00075	0.0119	CcSEcCtD
Vandetanib—RET—neck—thymus cancer	0.000748	0.00901	CbGeAlD
Vandetanib—BMPR1B—epithelium—thymus cancer	0.000732	0.00881	CbGeAlD
Vandetanib—Dysuria—Octreotide—thymus cancer	0.000729	0.0116	CcSEcCtD
Vandetanib—Upper respiratory tract infection—Octreotide—thymus cancer	0.000725	0.0115	CcSEcCtD
Vandetanib—Pollakiuria—Octreotide—thymus cancer	0.00072	0.0114	CcSEcCtD
Vandetanib—Weight decreased—Octreotide—thymus cancer	0.000706	0.0112	CcSEcCtD
Vandetanib—Hyperglycaemia—Octreotide—thymus cancer	0.000703	0.0111	CcSEcCtD
Vandetanib—Pneumonia—Octreotide—thymus cancer	0.000699	0.0111	CcSEcCtD
Vandetanib—FLT3—hematopoietic system—thymus cancer	0.000695	0.00836	CbGeAlD
Vandetanib—Depression—Octreotide—thymus cancer	0.000693	0.011	CcSEcCtD
Vandetanib—Urinary tract infection—Octreotide—thymus cancer	0.000676	0.0107	CcSEcCtD
Vandetanib—Conjunctivitis—Octreotide—thymus cancer	0.000676	0.0107	CcSEcCtD
Vandetanib—Haematuria—Octreotide—thymus cancer	0.000663	0.0105	CcSEcCtD
Vandetanib—Hepatobiliary disease—Octreotide—thymus cancer	0.000658	0.0104	CcSEcCtD
Vandetanib—Epistaxis—Octreotide—thymus cancer	0.000656	0.0104	CcSEcCtD
Vandetanib—Sinusitis—Octreotide—thymus cancer	0.000652	0.0103	CcSEcCtD
Vandetanib—LTK—lung—thymus cancer	0.00064	0.0077	CbGeAlD
Vandetanib—Bradycardia—Octreotide—thymus cancer	0.000635	0.0101	CcSEcCtD
Vandetanib—FLT4—hematopoietic system—thymus cancer	0.000631	0.0076	CbGeAlD
Vandetanib—RIPK2—hematopoietic system—thymus cancer	0.000628	0.00755	CbGeAlD
Vandetanib—PTK6—lung—thymus cancer	0.000613	0.00739	CbGeAlD
Vandetanib—IRAK4—hematopoietic system—thymus cancer	0.000613	0.00738	CbGeAlD
Vandetanib—PLK4—lymphoid tissue—thymus cancer	0.000612	0.00737	CbGeAlD
Vandetanib—EPHA5—pituitary gland—thymus cancer	0.000606	0.0073	CbGeAlD
Vandetanib—Visual impairment—Octreotide—thymus cancer	0.000602	0.00953	CcSEcCtD
Vandetanib—ERBB3—hematopoietic system—thymus cancer	0.000601	0.00723	CbGeAlD
Vandetanib—Cardiac disorder—Octreotide—thymus cancer	0.000579	0.00918	CcSEcCtD
Vandetanib—FLT4—epithelium—thymus cancer	0.000577	0.00694	CbGeAlD
Vandetanib—TYRO3—lymphoid tissue—thymus cancer	0.000575	0.00692	CbGeAlD
Vandetanib—RIPK2—epithelium—thymus cancer	0.000574	0.00691	CbGeAlD
Vandetanib—LYN—lymphoid tissue—thymus cancer	0.000572	0.00689	CbGeAlD
Vandetanib—MKNK1—hematopoietic system—thymus cancer	0.000564	0.00679	CbGeAlD
Vandetanib—Arrhythmia—Octreotide—thymus cancer	0.000558	0.00884	CcSEcCtD
Vandetanib—PLK4—bone marrow—thymus cancer	0.000558	0.00671	CbGeAlD
Vandetanib—KDR—neck—thymus cancer	0.000557	0.00671	CbGeAlD
Vandetanib—FGR—hematopoietic system—thymus cancer	0.000557	0.00671	CbGeAlD
Vandetanib—RET—hematopoietic system—thymus cancer	0.000557	0.00671	CbGeAlD
Vandetanib—AXL—hematopoietic system—thymus cancer	0.000555	0.00668	CbGeAlD
Vandetanib—Alopecia—Octreotide—thymus cancer	0.000552	0.00874	CcSEcCtD
Vandetanib—ERBB3—epithelium—thymus cancer	0.000549	0.00661	CbGeAlD
Vandetanib—Mental disorder—Octreotide—thymus cancer	0.000547	0.00867	CcSEcCtD
Vandetanib—Malnutrition—Octreotide—thymus cancer	0.000543	0.00861	CcSEcCtD
Vandetanib—Muscle spasms—Octreotide—thymus cancer	0.000522	0.00828	CcSEcCtD
Vandetanib—FYN—hematopoietic system—thymus cancer	0.000519	0.00625	CbGeAlD
Vandetanib—STK35—cardiac atrium—thymus cancer	0.000517	0.00622	CbGeAlD
Vandetanib—Vision blurred—Octreotide—thymus cancer	0.000512	0.00812	CcSEcCtD
Vandetanib—BMPR1B—thyroid gland—thymus cancer	0.000512	0.00616	CbGeAlD
Vandetanib—RET—epithelium—thymus cancer	0.000509	0.00613	CbGeAlD
Vandetanib—Tremor—Octreotide—thymus cancer	0.000509	0.00807	CcSEcCtD
Vandetanib—MAP4K5—hematopoietic system—thymus cancer	0.000507	0.00611	CbGeAlD
Vandetanib—TEK—hematopoietic system—thymus cancer	0.000507	0.00611	CbGeAlD
Vandetanib—PLK4—lung—thymus cancer	0.000505	0.00608	CbGeAlD
Vandetanib—ABL2—pituitary gland—thymus cancer	0.000492	0.00592	CbGeAlD
Vandetanib—FLT3—lymphoid tissue—thymus cancer	0.000489	0.00589	CbGeAlD
Vandetanib—PDGFRB—neck—thymus cancer	0.000482	0.00581	CbGeAlD
Vandetanib—Loss of consciousness—Octreotide—thymus cancer	0.000478	0.00757	CcSEcCtD
Vandetanib—RIPK2—cardiac atrium—thymus cancer	0.000477	0.00574	CbGeAlD
Vandetanib—VEGFA—cardiac atrium—thymus cancer	0.000475	0.00572	CbGeAlD
Vandetanib—Cough—Octreotide—thymus cancer	0.000474	0.00751	CcSEcCtD
Vandetanib—Convulsion—Octreotide—thymus cancer	0.000471	0.00746	CcSEcCtD
Vandetanib—Hypertension—Octreotide—thymus cancer	0.000469	0.00744	CcSEcCtD
Vandetanib—YES1—hematopoietic system—thymus cancer	0.000469	0.00564	CbGeAlD
Vandetanib—RIPK2—pituitary gland—thymus cancer	0.000466	0.0056	CbGeAlD
Vandetanib—BMPR1B—lung—thymus cancer	0.000465	0.0056	CbGeAlD
Vandetanib—MAP3K19—lung—thymus cancer	0.000465	0.0056	CbGeAlD
Vandetanib—STK10—hematopoietic system—thymus cancer	0.000464	0.00559	CbGeAlD
Vandetanib—VEGFA—pituitary gland—thymus cancer	0.000464	0.00559	CbGeAlD
Vandetanib—TEK—epithelium—thymus cancer	0.000464	0.00558	CbGeAlD
Vandetanib—Arthralgia—Octreotide—thymus cancer	0.000463	0.00733	CcSEcCtD
Vandetanib—Chest pain—Octreotide—thymus cancer	0.000463	0.00733	CcSEcCtD
Vandetanib—FMO1—pituitary gland—thymus cancer	0.000462	0.00556	CbGeAlD
Vandetanib—Anxiety—Octreotide—thymus cancer	0.000461	0.00731	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Octreotide—thymus cancer	0.000459	0.00728	CcSEcCtD
Vandetanib—IRAK4—pituitary gland—thymus cancer	0.000455	0.00547	CbGeAlD
Vandetanib—Dry mouth—Octreotide—thymus cancer	0.000452	0.00717	CcSEcCtD
Vandetanib—SRC—hematopoietic system—thymus cancer	0.000451	0.00543	CbGeAlD
Vandetanib—FLT3—bone marrow—thymus cancer	0.000445	0.00536	CbGeAlD
Vandetanib—FLT4—lymphoid tissue—thymus cancer	0.000444	0.00535	CbGeAlD
Vandetanib—Oedema—Octreotide—thymus cancer	0.000443	0.00703	CcSEcCtD
Vandetanib—BLK—lymph node—thymus cancer	0.000443	0.00533	CbGeAlD
Vandetanib—Infection—Octreotide—thymus cancer	0.000441	0.00698	CcSEcCtD
Vandetanib—LTK—lymph node—thymus cancer	0.000438	0.00527	CbGeAlD
Vandetanib—STK35—thyroid gland—thymus cancer	0.000435	0.00524	CbGeAlD
Vandetanib—Nervous system disorder—Octreotide—thymus cancer	0.000435	0.00689	CcSEcCtD
Vandetanib—Thrombocytopenia—Octreotide—thymus cancer	0.000434	0.00688	CcSEcCtD
Vandetanib—IRAK4—lymphoid tissue—thymus cancer	0.000431	0.00519	CbGeAlD
Vandetanib—Skin disorder—Octreotide—thymus cancer	0.000431	0.00683	CcSEcCtD
Vandetanib—MKNK1—cardiac atrium—thymus cancer	0.000428	0.00516	CbGeAlD
Vandetanib—ABL2—thyroid gland—thymus cancer	0.000424	0.00511	CbGeAlD
Vandetanib—ERBB3—lymphoid tissue—thymus cancer	0.000423	0.00509	CbGeAlD
Vandetanib—AXL—cardiac atrium—thymus cancer	0.000421	0.00507	CbGeAlD
Vandetanib—MKNK1—pituitary gland—thymus cancer	0.000418	0.00504	CbGeAlD
Vandetanib—KDR—hematopoietic system—thymus cancer	0.000415	0.00499	CbGeAlD
Vandetanib—EGFR—thyroid gland—thymus cancer	0.000414	0.00498	CbGeAlD
Vandetanib—RET—pituitary gland—thymus cancer	0.000413	0.00497	CbGeAlD
Vandetanib—FGR—pituitary gland—thymus cancer	0.000413	0.00497	CbGeAlD
Vandetanib—SRC—epithelium—thymus cancer	0.000412	0.00496	CbGeAlD
Vandetanib—AXL—pituitary gland—thymus cancer	0.000412	0.00495	CbGeAlD
Vandetanib—SLK—cardiac atrium—thymus cancer	0.000406	0.00488	CbGeAlD
Vandetanib—FLT4—bone marrow—thymus cancer	0.000405	0.00487	CbGeAlD
Vandetanib—Musculoskeletal discomfort—Octreotide—thymus cancer	0.000404	0.0064	CcSEcCtD
Vandetanib—FLT3—lung—thymus cancer	0.000403	0.00486	CbGeAlD
Vandetanib—FLT4—thyroid gland—thymus cancer	0.000403	0.00486	CbGeAlD
Vandetanib—RIPK2—bone marrow—thymus cancer	0.000402	0.00484	CbGeAlD
Vandetanib—RIPK2—thyroid gland—thymus cancer	0.000401	0.00483	CbGeAlD
Vandetanib—VEGFA—bone marrow—thymus cancer	0.000401	0.00483	CbGeAlD
Vandetanib—Insomnia—Octreotide—thymus cancer	0.000401	0.00636	CcSEcCtD
Vandetanib—VEGFA—thyroid gland—thymus cancer	0.0004	0.00482	CbGeAlD
Vandetanib—FMO3—pituitary gland—thymus cancer	0.000399	0.0048	CbGeAlD
Vandetanib—Paraesthesia—Octreotide—thymus cancer	0.000398	0.00631	CcSEcCtD
Vandetanib—FMO1—thyroid gland—thymus cancer	0.000398	0.00479	CbGeAlD
Vandetanib—MKNK1—lymphoid tissue—thymus cancer	0.000397	0.00478	CbGeAlD
Vandetanib—SLK—pituitary gland—thymus cancer	0.000396	0.00477	CbGeAlD
Vandetanib—Dyspnoea—Octreotide—thymus cancer	0.000395	0.00627	CcSEcCtD
Vandetanib—STK35—lung—thymus cancer	0.000395	0.00476	CbGeAlD
Vandetanib—FYN—cardiac atrium—thymus cancer	0.000394	0.00475	CbGeAlD
Vandetanib—IRAK4—bone marrow—thymus cancer	0.000393	0.00473	CbGeAlD
Vandetanib—FGR—lymphoid tissue—thymus cancer	0.000392	0.00472	CbGeAlD
Vandetanib—RET—lymphoid tissue—thymus cancer	0.000392	0.00472	CbGeAlD
Vandetanib—IRAK4—thyroid gland—thymus cancer	0.000392	0.00472	CbGeAlD
Vandetanib—AXL—lymphoid tissue—thymus cancer	0.000391	0.0047	CbGeAlD
Vandetanib—Dyspepsia—Octreotide—thymus cancer	0.00039	0.00619	CcSEcCtD
Vandetanib—Decreased appetite—Octreotide—thymus cancer	0.000385	0.00611	CcSEcCtD
Vandetanib—TEK—cardiac atrium—thymus cancer	0.000385	0.00464	CbGeAlD
Vandetanib—MAP4K5—cardiac atrium—thymus cancer	0.000385	0.00464	CbGeAlD
Vandetanib—ABL2—lung—thymus cancer	0.000385	0.00464	CbGeAlD
Vandetanib—FYN—pituitary gland—thymus cancer	0.000385	0.00464	CbGeAlD
Vandetanib—ERBB3—thyroid gland—thymus cancer	0.000384	0.00462	CbGeAlD
Vandetanib—Gastrointestinal disorder—Octreotide—thymus cancer	0.000383	0.00607	CcSEcCtD
Vandetanib—Fatigue—Octreotide—thymus cancer	0.000382	0.00606	CcSEcCtD
Vandetanib—Pain—Octreotide—thymus cancer	0.000379	0.00601	CcSEcCtD
Vandetanib—Constipation—Octreotide—thymus cancer	0.000379	0.00601	CcSEcCtD
Vandetanib—KDR—epithelium—thymus cancer	0.000379	0.00456	CbGeAlD
Vandetanib—MAP4K5—pituitary gland—thymus cancer	0.000376	0.00453	CbGeAlD
Vandetanib—TEK—pituitary gland—thymus cancer	0.000376	0.00453	CbGeAlD
Vandetanib—EGFR—lung—thymus cancer	0.000376	0.00453	CbGeAlD
Vandetanib—EPHB6—cardiac atrium—thymus cancer	0.000368	0.00443	CbGeAlD
Vandetanib—FLT4—lung—thymus cancer	0.000366	0.00441	CbGeAlD
Vandetanib—FYN—lymphoid tissue—thymus cancer	0.000366	0.0044	CbGeAlD
Vandetanib—RIPK2—lung—thymus cancer	0.000364	0.00439	CbGeAlD
Vandetanib—VEGFA—lung—thymus cancer	0.000363	0.00438	CbGeAlD
Vandetanib—Gastrointestinal pain—Octreotide—thymus cancer	0.000363	0.00575	CcSEcCtD
Vandetanib—FMO1—lung—thymus cancer	0.000362	0.00435	CbGeAlD
Vandetanib—MKNK1—bone marrow—thymus cancer	0.000362	0.00435	CbGeAlD
Vandetanib—MKNK1—thyroid gland—thymus cancer	0.000361	0.00434	CbGeAlD
Vandetanib—EPHB6—pituitary gland—thymus cancer	0.00036	0.00433	CbGeAlD
Vandetanib—PDGFRB—hematopoietic system—thymus cancer	0.000359	0.00432	CbGeAlD
Vandetanib—TEK—lymphoid tissue—thymus cancer	0.000357	0.0043	CbGeAlD
Vandetanib—MAP4K5—lymphoid tissue—thymus cancer	0.000357	0.0043	CbGeAlD
Vandetanib—LCK—bone marrow—thymus cancer	0.000357	0.0043	CbGeAlD
Vandetanib—FGR—bone marrow—thymus cancer	0.000357	0.0043	CbGeAlD
Vandetanib—FGR—thyroid gland—thymus cancer	0.000356	0.00429	CbGeAlD
Vandetanib—LCK—thyroid gland—thymus cancer	0.000356	0.00429	CbGeAlD
Vandetanib—RET—thyroid gland—thymus cancer	0.000356	0.00429	CbGeAlD
Vandetanib—IRAK4—lung—thymus cancer	0.000356	0.00428	CbGeAlD
Vandetanib—YES1—cardiac atrium—thymus cancer	0.000356	0.00428	CbGeAlD
Vandetanib—AXL—thyroid gland—thymus cancer	0.000355	0.00427	CbGeAlD
Vandetanib—Abdominal pain—Octreotide—thymus cancer	0.000351	0.00556	CcSEcCtD
Vandetanib—Body temperature increased—Octreotide—thymus cancer	0.000351	0.00556	CcSEcCtD
Vandetanib—ERBB3—lung—thymus cancer	0.000349	0.0042	CbGeAlD
Vandetanib—YES1—pituitary gland—thymus cancer	0.000348	0.00419	CbGeAlD
Vandetanib—PLK4—lymph node—thymus cancer	0.000346	0.00416	CbGeAlD
Vandetanib—FMO3—thyroid gland—thymus cancer	0.000344	0.00414	CbGeAlD
Vandetanib—SLK—bone marrow—thymus cancer	0.000342	0.00412	CbGeAlD
Vandetanib—SRC—cardiac atrium—thymus cancer	0.000342	0.00412	CbGeAlD
Vandetanib—SLK—thyroid gland—thymus cancer	0.000342	0.00411	CbGeAlD
Vandetanib—ORM1—hematopoietic system—thymus cancer	0.000337	0.00405	CbGeAlD
Vandetanib—FYN—bone marrow—thymus cancer	0.000333	0.00401	CbGeAlD
Vandetanib—FYN—thyroid gland—thymus cancer	0.000332	0.004	CbGeAlD
Vandetanib—YES1—lymphoid tissue—thymus cancer	0.00033	0.00397	CbGeAlD
Vandetanib—PDGFRB—epithelium—thymus cancer	0.000328	0.00395	CbGeAlD
Vandetanib—MKNK1—lung—thymus cancer	0.000328	0.00394	CbGeAlD
Vandetanib—STK10—lymphoid tissue—thymus cancer	0.000327	0.00394	CbGeAlD
Vandetanib—MAP4K5—bone marrow—thymus cancer	0.000325	0.00392	CbGeAlD
Vandetanib—TEK—thyroid gland—thymus cancer	0.000324	0.00391	CbGeAlD
Vandetanib—MAP4K5—thyroid gland—thymus cancer	0.000324	0.00391	CbGeAlD
Vandetanib—FGR—lung—thymus cancer	0.000324	0.0039	CbGeAlD
Vandetanib—LCK—lung—thymus cancer	0.000324	0.0039	CbGeAlD
Vandetanib—AXL—lung—thymus cancer	0.000322	0.00388	CbGeAlD
Vandetanib—ABL1—hematopoietic system—thymus cancer	0.00032	0.00385	CbGeAlD
Vandetanib—Asthenia—Octreotide—thymus cancer	0.000318	0.00504	CcSEcCtD
Vandetanib—BMPR1B—lymph node—thymus cancer	0.000318	0.00383	CbGeAlD
Vandetanib—SRC—lymphoid tissue—thymus cancer	0.000317	0.00382	CbGeAlD
Vandetanib—MAP2K5—cardiac atrium—thymus cancer	0.000315	0.00379	CbGeAlD
Vandetanib—KDR—cardiac atrium—thymus cancer	0.000315	0.00379	CbGeAlD
Vandetanib—Pruritus—Octreotide—thymus cancer	0.000314	0.00497	CcSEcCtD
Vandetanib—FMO3—lung—thymus cancer	0.000312	0.00376	CbGeAlD
Vandetanib—SLK—lung—thymus cancer	0.00031	0.00373	CbGeAlD
Vandetanib—EPHB6—thyroid gland—thymus cancer	0.00031	0.00373	CbGeAlD
Vandetanib—MAP2K5—pituitary gland—thymus cancer	0.000308	0.0037	CbGeAlD
Vandetanib—KDR—pituitary gland—thymus cancer	0.000308	0.0037	CbGeAlD
Vandetanib—Diarrhoea—Octreotide—thymus cancer	0.000303	0.00481	CcSEcCtD
Vandetanib—FYN—lung—thymus cancer	0.000302	0.00363	CbGeAlD
Vandetanib—YES1—bone marrow—thymus cancer	0.0003	0.00362	CbGeAlD
Vandetanib—YES1—thyroid gland—thymus cancer	0.0003	0.00361	CbGeAlD
Vandetanib—STK10—bone marrow—thymus cancer	0.000298	0.00358	CbGeAlD
Vandetanib—STK10—thyroid gland—thymus cancer	0.000297	0.00358	CbGeAlD
Vandetanib—TEK—lung—thymus cancer	0.000295	0.00355	CbGeAlD
Vandetanib—MAP4K5—lung—thymus cancer	0.000295	0.00355	CbGeAlD
Vandetanib—Dizziness—Octreotide—thymus cancer	0.000293	0.00465	CcSEcCtD
Vandetanib—KDR—lymphoid tissue—thymus cancer	0.000292	0.00352	CbGeAlD
Vandetanib—SRC—thyroid gland—thymus cancer	0.000288	0.00347	CbGeAlD
Vandetanib—Vomiting—Octreotide—thymus cancer	0.000282	0.00447	CcSEcCtD
Vandetanib—EPHB6—lung—thymus cancer	0.000282	0.00339	CbGeAlD
Vandetanib—Rash—Octreotide—thymus cancer	0.00028	0.00443	CcSEcCtD
Vandetanib—Dermatitis—Octreotide—thymus cancer	0.000279	0.00443	CcSEcCtD
Vandetanib—Headache—Octreotide—thymus cancer	0.000278	0.0044	CcSEcCtD
Vandetanib—FLT3—lymph node—thymus cancer	0.000276	0.00332	CbGeAlD
Vandetanib—PDGFRB—cardiac atrium—thymus cancer	0.000273	0.00328	CbGeAlD
Vandetanib—YES1—lung—thymus cancer	0.000272	0.00328	CbGeAlD
Vandetanib—STK35—lymph node—thymus cancer	0.00027	0.00325	CbGeAlD
Vandetanib—STK10—lung—thymus cancer	0.00027	0.00325	CbGeAlD
Vandetanib—PDGFRB—pituitary gland—thymus cancer	0.000266	0.00321	CbGeAlD
Vandetanib—KDR—bone marrow—thymus cancer	0.000266	0.0032	CbGeAlD
Vandetanib—KDR—thyroid gland—thymus cancer	0.000265	0.00319	CbGeAlD
Vandetanib—MAP2K5—thyroid gland—thymus cancer	0.000265	0.00319	CbGeAlD
Vandetanib—ABL2—lymph node—thymus cancer	0.000263	0.00317	CbGeAlD
Vandetanib—Nausea—Octreotide—thymus cancer	0.000263	0.00417	CcSEcCtD
Vandetanib—SRC—lung—thymus cancer	0.000262	0.00315	CbGeAlD
Vandetanib—EGFR—lymph node—thymus cancer	0.000257	0.0031	CbGeAlD
Vandetanib—PDGFRB—lymphoid tissue—thymus cancer	0.000253	0.00304	CbGeAlD
Vandetanib—FLT4—lymph node—thymus cancer	0.000251	0.00302	CbGeAlD
Vandetanib—RIPK2—lymph node—thymus cancer	0.000249	0.003	CbGeAlD
Vandetanib—VEGFA—lymph node—thymus cancer	0.000249	0.00299	CbGeAlD
Vandetanib—FMO1—lymph node—thymus cancer	0.000247	0.00298	CbGeAlD
Vandetanib—IRAK4—lymph node—thymus cancer	0.000243	0.00293	CbGeAlD
Vandetanib—ABL1—cardiac atrium—thymus cancer	0.000243	0.00292	CbGeAlD
Vandetanib—KDR—lung—thymus cancer	0.000241	0.0029	CbGeAlD
Vandetanib—MAP2K5—lung—thymus cancer	0.000241	0.0029	CbGeAlD
Vandetanib—ERBB3—lymph node—thymus cancer	0.000239	0.00287	CbGeAlD
Vandetanib—ABL1—pituitary gland—thymus cancer	0.000237	0.00286	CbGeAlD
Vandetanib—PDGFRB—bone marrow—thymus cancer	0.00023	0.00277	CbGeAlD
Vandetanib—PDGFRB—thyroid gland—thymus cancer	0.00023	0.00276	CbGeAlD
Vandetanib—ABL1—lymphoid tissue—thymus cancer	0.000225	0.00271	CbGeAlD
Vandetanib—MKNK1—lymph node—thymus cancer	0.000224	0.0027	CbGeAlD
Vandetanib—LCK—lymph node—thymus cancer	0.000221	0.00266	CbGeAlD
Vandetanib—FGR—lymph node—thymus cancer	0.000221	0.00266	CbGeAlD
Vandetanib—RET—lymph node—thymus cancer	0.000221	0.00266	CbGeAlD
Vandetanib—AXL—lymph node—thymus cancer	0.00022	0.00265	CbGeAlD
Vandetanib—ORM1—bone marrow—thymus cancer	0.000216	0.0026	CbGeAlD
Vandetanib—FMO3—lymph node—thymus cancer	0.000214	0.00257	CbGeAlD
Vandetanib—SLK—lymph node—thymus cancer	0.000212	0.00255	CbGeAlD
Vandetanib—PDGFRB—lung—thymus cancer	0.000208	0.00251	CbGeAlD
Vandetanib—FYN—lymph node—thymus cancer	0.000206	0.00248	CbGeAlD
Vandetanib—ABL1—bone marrow—thymus cancer	0.000205	0.00247	CbGeAlD
Vandetanib—ABL1—thyroid gland—thymus cancer	0.000205	0.00246	CbGeAlD
Vandetanib—MAP4K5—lymph node—thymus cancer	0.000202	0.00243	CbGeAlD
Vandetanib—TEK—lymph node—thymus cancer	0.000202	0.00243	CbGeAlD
Vandetanib—ORM1—lung—thymus cancer	0.000196	0.00235	CbGeAlD
Vandetanib—EPHB6—lymph node—thymus cancer	0.000193	0.00232	CbGeAlD
Vandetanib—YES1—lymph node—thymus cancer	0.000186	0.00224	CbGeAlD
Vandetanib—ABL1—lung—thymus cancer	0.000186	0.00224	CbGeAlD
Vandetanib—ABCC1—cardiac atrium—thymus cancer	0.000185	0.00223	CbGeAlD
Vandetanib—STK10—lymph node—thymus cancer	0.000184	0.00222	CbGeAlD
Vandetanib—ABCC1—pituitary gland—thymus cancer	0.000181	0.00218	CbGeAlD
Vandetanib—SRC—lymph node—thymus cancer	0.000179	0.00216	CbGeAlD
Vandetanib—MAP2K5—lymph node—thymus cancer	0.000165	0.00198	CbGeAlD
Vandetanib—KDR—lymph node—thymus cancer	0.000165	0.00198	CbGeAlD
Vandetanib—ABCC1—thyroid gland—thymus cancer	0.000156	0.00188	CbGeAlD
Vandetanib—ABCG2—pituitary gland—thymus cancer	0.00015	0.0018	CbGeAlD
Vandetanib—PDGFRB—lymph node—thymus cancer	0.000143	0.00172	CbGeAlD
Vandetanib—ABCC1—lung—thymus cancer	0.000142	0.0017	CbGeAlD
Vandetanib—CYP3A4—hematopoietic system—thymus cancer	0.000141	0.00169	CbGeAlD
Vandetanib—ORM1—lymph node—thymus cancer	0.000134	0.00161	CbGeAlD
Vandetanib—ABCG2—bone marrow—thymus cancer	0.000129	0.00156	CbGeAlD
Vandetanib—ABCG2—thyroid gland—thymus cancer	0.000129	0.00155	CbGeAlD
Vandetanib—ABL1—lymph node—thymus cancer	0.000127	0.00153	CbGeAlD
Vandetanib—ALB—lymph node—thymus cancer	0.000117	0.00141	CbGeAlD
Vandetanib—ABCG2—lung—thymus cancer	0.000117	0.00141	CbGeAlD
Vandetanib—ABCC1—lymph node—thymus cancer	9.68e-05	0.00117	CbGeAlD
Vandetanib—ABCG2—lymph node—thymus cancer	8.01e-05	0.000965	CbGeAlD
Vandetanib—EGFR—Signaling by PDGF—AKT1—thymus cancer	1.69e-05	0.000251	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—KIT—thymus cancer	1.69e-05	0.000251	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MAML2—thymus cancer	1.69e-05	0.000251	CbGpPWpGaD
Vandetanib—FYN—Platelet activation, signaling and aggregation—AKT1—thymus cancer	1.68e-05	0.000249	CbGpPWpGaD
Vandetanib—LCK—Signaling by FGFR in disease—AKT1—thymus cancer	1.67e-05	0.000248	CbGpPWpGaD
Vandetanib—LCK—DAP12 interactions—AKT1—thymus cancer	1.67e-05	0.000248	CbGpPWpGaD
Vandetanib—LCK—Fc epsilon receptor (FCERI) signaling—AKT1—thymus cancer	1.67e-05	0.000248	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MAML2—thymus cancer	1.66e-05	0.000247	CbGpPWpGaD
Vandetanib—LCK—Signaling by EGFR—AKT1—thymus cancer	1.65e-05	0.000246	CbGpPWpGaD
Vandetanib—SRC—Integrated Pancreatic Cancer Pathway—TP53—thymus cancer	1.65e-05	0.000244	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—CD8A—thymus cancer	1.64e-05	0.000244	CbGpPWpGaD
Vandetanib—LCK—Signaling by EGFR in Cancer—AKT1—thymus cancer	1.64e-05	0.000243	CbGpPWpGaD
Vandetanib—EGFR—Focal Adhesion—AKT1—thymus cancer	1.64e-05	0.000243	CbGpPWpGaD
Vandetanib—LCK—Signaling by PDGF—AKT1—thymus cancer	1.63e-05	0.000242	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—KIT—thymus cancer	1.63e-05	0.000242	CbGpPWpGaD
Vandetanib—EGFR—Integrated Pancreatic Cancer Pathway—AKT1—thymus cancer	1.63e-05	0.000242	CbGpPWpGaD
Vandetanib—IRAK4—Immune System—IL2—thymus cancer	1.63e-05	0.000242	CbGpPWpGaD
Vandetanib—LYN—Hemostasis—IL2—thymus cancer	1.62e-05	0.000241	CbGpPWpGaD
Vandetanib—PDGFRB—Innate Immune System—CD4—thymus cancer	1.62e-05	0.00024	CbGpPWpGaD
Vandetanib—YES1—Immune System—KIT—thymus cancer	1.62e-05	0.00024	CbGpPWpGaD
Vandetanib—ABL1—Hemostasis—IL2—thymus cancer	1.61e-05	0.000239	CbGpPWpGaD
Vandetanib—LYN—Immune System—CD8A—thymus cancer	1.61e-05	0.000239	CbGpPWpGaD
Vandetanib—EGFR—B Cell Activation—AKT1—thymus cancer	1.6e-05	0.000238	CbGpPWpGaD
Vandetanib—ABL1—Immune System—CD8A—thymus cancer	1.6e-05	0.000238	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—CD4—thymus cancer	1.6e-05	0.000238	CbGpPWpGaD
Vandetanib—FYN—Hemostasis—IL2—thymus cancer	1.59e-05	0.000237	CbGpPWpGaD
Vandetanib—SRC—Downstream signal transduction—AKT1—thymus cancer	1.59e-05	0.000237	CbGpPWpGaD
Vandetanib—SRC—Signaling by FGFR—AKT1—thymus cancer	1.58e-05	0.000235	CbGpPWpGaD
Vandetanib—SRC—EGF/EGFR Signaling Pathway—AKT1—thymus cancer	1.58e-05	0.000235	CbGpPWpGaD
Vandetanib—LYN—Innate Immune System—CD4—thymus cancer	1.58e-05	0.000235	CbGpPWpGaD
Vandetanib—FYN—Immune System—CD8A—thymus cancer	1.58e-05	0.000235	CbGpPWpGaD
Vandetanib—ABL1—Innate Immune System—CD4—thymus cancer	1.58e-05	0.000234	CbGpPWpGaD
Vandetanib—SRC—Signaling by ERBB2—AKT1—thymus cancer	1.58e-05	0.000234	CbGpPWpGaD
Vandetanib—FYN—Innate Immune System—CD4—thymus cancer	1.56e-05	0.000232	CbGpPWpGaD
Vandetanib—PDGFRB—Adaptive Immune System—CD4—thymus cancer	1.55e-05	0.000231	CbGpPWpGaD
Vandetanib—LCK—B Cell Activation—AKT1—thymus cancer	1.54e-05	0.000229	CbGpPWpGaD
Vandetanib—ALB—Platelet activation, signaling and aggregation—IL2—thymus cancer	1.54e-05	0.000229	CbGpPWpGaD
Vandetanib—BLK—Immune System—CD4—thymus cancer	1.54e-05	0.000229	CbGpPWpGaD
Vandetanib—FGR—Immune System—CD4—thymus cancer	1.53e-05	0.000228	CbGpPWpGaD
Vandetanib—EGFR—NGF signalling via TRKA from the plasma membrane—AKT1—thymus cancer	1.53e-05	0.000228	CbGpPWpGaD
Vandetanib—LYN—Adaptive Immune System—CD4—thymus cancer	1.52e-05	0.000226	CbGpPWpGaD
Vandetanib—IRAK4—Innate Immune System—AKT1—thymus cancer	1.51e-05	0.000225	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—KIT—thymus cancer	1.5e-05	0.000223	CbGpPWpGaD
Vandetanib—FYN—Adaptive Immune System—CD4—thymus cancer	1.5e-05	0.000223	CbGpPWpGaD
Vandetanib—LCK—NGF signalling via TRKA from the plasma membrane—AKT1—thymus cancer	1.48e-05	0.000219	CbGpPWpGaD
Vandetanib—SRC—Signaling by FGFR in disease—AKT1—thymus cancer	1.48e-05	0.000219	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—IL2—thymus cancer	1.47e-05	0.000219	CbGpPWpGaD
Vandetanib—SRC—Signaling by EGFR—AKT1—thymus cancer	1.46e-05	0.000217	CbGpPWpGaD
Vandetanib—FGR—Hemostasis—AKT1—thymus cancer	1.46e-05	0.000217	CbGpPWpGaD
Vandetanib—SRC—Signaling by EGFR in Cancer—AKT1—thymus cancer	1.45e-05	0.000215	CbGpPWpGaD
Vandetanib—SRC—Signaling by PDGF—AKT1—thymus cancer	1.44e-05	0.000214	CbGpPWpGaD
Vandetanib—VEGFA—Hemostasis—TP53—thymus cancer	1.44e-05	0.000214	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—KIT—thymus cancer	1.44e-05	0.000214	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MAML2—thymus cancer	1.44e-05	0.000214	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling by NGF—AKT1—thymus cancer	1.42e-05	0.00021	CbGpPWpGaD
Vandetanib—BLK—Immune System—IL2—thymus cancer	1.42e-05	0.00021	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—IL2—thymus cancer	1.42e-05	0.00021	CbGpPWpGaD
Vandetanib—FGR—Immune System—IL2—thymus cancer	1.41e-05	0.00021	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—CD4—thymus cancer	1.41e-05	0.000209	CbGpPWpGaD
Vandetanib—LCK—Platelet activation, signaling and aggregation—AKT1—thymus cancer	1.4e-05	0.000207	CbGpPWpGaD
Vandetanib—SRC—Focal Adhesion—AKT1—thymus cancer	1.4e-05	0.000207	CbGpPWpGaD
Vandetanib—SRC—Membrane Trafficking—AKT1—thymus cancer	1.4e-05	0.000207	CbGpPWpGaD
Vandetanib—YES1—Hemostasis—TP53—thymus cancer	1.39e-05	0.000207	CbGpPWpGaD
Vandetanib—SRC—Integrated Pancreatic Cancer Pathway—AKT1—thymus cancer	1.39e-05	0.000206	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MAML2—thymus cancer	1.39e-05	0.000206	CbGpPWpGaD
Vandetanib—KDR—Developmental Biology—AKT1—thymus cancer	1.38e-05	0.000205	CbGpPWpGaD
Vandetanib—RIPK2—Innate Immune System—AKT1—thymus cancer	1.37e-05	0.000204	CbGpPWpGaD
Vandetanib—EGFR—Immune System—CD8A—thymus cancer	1.37e-05	0.000203	CbGpPWpGaD
Vandetanib—FYN—Signaling by NGF—AKT1—thymus cancer	1.36e-05	0.000203	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—KIT—thymus cancer	1.35e-05	0.000201	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—CD4—thymus cancer	1.35e-05	0.0002	CbGpPWpGaD
Vandetanib—LCK—Hemostasis—IL2—thymus cancer	1.33e-05	0.000197	CbGpPWpGaD
Vandetanib—LCK—Immune System—CD8A—thymus cancer	1.32e-05	0.000196	CbGpPWpGaD
Vandetanib—RIPK2—Adaptive Immune System—AKT1—thymus cancer	1.32e-05	0.000195	CbGpPWpGaD
Vandetanib—FGR—Innate Immune System—AKT1—thymus cancer	1.31e-05	0.000195	CbGpPWpGaD
Vandetanib—AXL—Signaling Pathways—TP53—thymus cancer	1.31e-05	0.000195	CbGpPWpGaD
Vandetanib—SRC—NGF signalling via TRKA from the plasma membrane—AKT1—thymus cancer	1.31e-05	0.000194	CbGpPWpGaD
Vandetanib—ERBB3—Disease—CD4—thymus cancer	1.3e-05	0.000193	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—CD4—thymus cancer	1.3e-05	0.000193	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—IL2—thymus cancer	1.3e-05	0.000193	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—CD4—thymus cancer	1.29e-05	0.000192	CbGpPWpGaD
Vandetanib—BLK—Adaptive Immune System—AKT1—thymus cancer	1.27e-05	0.000188	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—CD4—thymus cancer	1.25e-05	0.000185	CbGpPWpGaD
Vandetanib—VEGFA—Developmental Biology—AKT1—thymus cancer	1.24e-05	0.000185	CbGpPWpGaD
Vandetanib—YES1—Immune System—CD4—thymus cancer	1.24e-05	0.000184	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—KIT—thymus cancer	1.24e-05	0.000184	CbGpPWpGaD
Vandetanib—SRC—Platelet activation, signaling and aggregation—AKT1—thymus cancer	1.24e-05	0.000184	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—KIT—thymus cancer	1.23e-05	0.000183	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MAML2—thymus cancer	1.23e-05	0.000182	CbGpPWpGaD
Vandetanib—VEGFA—Hemostasis—AKT1—thymus cancer	1.22e-05	0.000181	CbGpPWpGaD
Vandetanib—ERBB3—Innate Immune System—AKT1—thymus cancer	1.21e-05	0.000179	CbGpPWpGaD
Vandetanib—LYN—Immune System—KIT—thymus cancer	1.21e-05	0.000179	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—KIT—thymus cancer	1.21e-05	0.000179	CbGpPWpGaD
Vandetanib—ABL1—Immune System—KIT—thymus cancer	1.2e-05	0.000178	CbGpPWpGaD
Vandetanib—YES1—Developmental Biology—AKT1—thymus cancer	1.2e-05	0.000178	CbGpPWpGaD
Vandetanib—BMPR1B—Signaling Pathways—TP53—thymus cancer	1.2e-05	0.000178	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—KIT—thymus cancer	1.19e-05	0.000177	CbGpPWpGaD
Vandetanib—FYN—Immune System—KIT—thymus cancer	1.19e-05	0.000176	CbGpPWpGaD
Vandetanib—EGFR—Signaling by NGF—AKT1—thymus cancer	1.18e-05	0.000175	CbGpPWpGaD
Vandetanib—YES1—Hemostasis—AKT1—thymus cancer	1.18e-05	0.000175	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—IL2—thymus cancer	1.18e-05	0.000175	CbGpPWpGaD
Vandetanib—SRC—Immune System—CD8A—thymus cancer	1.17e-05	0.000173	CbGpPWpGaD
Vandetanib—ERBB3—Adaptive Immune System—AKT1—thymus cancer	1.16e-05	0.000172	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—CD4—thymus cancer	1.15e-05	0.000171	CbGpPWpGaD
Vandetanib—YES1—Immune System—IL2—thymus cancer	1.14e-05	0.000169	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—KIT—thymus cancer	1.14e-05	0.000169	CbGpPWpGaD
Vandetanib—LCK—Signaling by NGF—AKT1—thymus cancer	1.14e-05	0.000169	CbGpPWpGaD
Vandetanib—AXL—Signaling Pathways—AKT1—thymus cancer	1.11e-05	0.000164	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—CD4—thymus cancer	1.1e-05	0.000164	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—TP53—thymus cancer	1.1e-05	0.000163	CbGpPWpGaD
Vandetanib—FYN—Disease—KIT—thymus cancer	1.1e-05	0.000163	CbGpPWpGaD
Vandetanib—MKNK1—Disease—AKT1—thymus cancer	1.1e-05	0.000163	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—KIT—thymus cancer	1.08e-05	0.000161	CbGpPWpGaD
Vandetanib—YES1—Innate Immune System—AKT1—thymus cancer	1.06e-05	0.000157	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—KIT—thymus cancer	1.05e-05	0.000155	CbGpPWpGaD
Vandetanib—LYN—Hemostasis—TP53—thymus cancer	1.04e-05	0.000154	CbGpPWpGaD
Vandetanib—ABL1—Hemostasis—TP53—thymus cancer	1.04e-05	0.000154	CbGpPWpGaD
Vandetanib—EGFR—Immune System—KIT—thymus cancer	1.03e-05	0.000152	CbGpPWpGaD
Vandetanib—FYN—Hemostasis—TP53—thymus cancer	1.02e-05	0.000152	CbGpPWpGaD
Vandetanib—YES1—Adaptive Immune System—AKT1—thymus cancer	1.02e-05	0.000151	CbGpPWpGaD
Vandetanib—BMPR1B—Signaling Pathways—AKT1—thymus cancer	1.01e-05	0.00015	CbGpPWpGaD
Vandetanib—SRC—Signaling by NGF—AKT1—thymus cancer	1.01e-05	0.000149	CbGpPWpGaD
Vandetanib—ABCC1—Disease—KIT—thymus cancer	1.01e-05	0.000149	CbGpPWpGaD
Vandetanib—LCK—Immune System—KIT—thymus cancer	9.89e-06	0.000147	CbGpPWpGaD
Vandetanib—FMO1—Metabolism—AKT1—thymus cancer	9.68e-06	0.000144	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—IL2—thymus cancer	9.51e-06	0.000141	CbGpPWpGaD
Vandetanib—EGFR—Disease—KIT—thymus cancer	9.48e-06	0.000141	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—CD4—thymus cancer	9.43e-06	0.00014	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—AKT1—thymus cancer	9.26e-06	0.000138	CbGpPWpGaD
Vandetanib—LYN—Immune System—CD4—thymus cancer	9.23e-06	0.000137	CbGpPWpGaD
Vandetanib—ABL1—Immune System—CD4—thymus cancer	9.19e-06	0.000136	CbGpPWpGaD
Vandetanib—LCK—Disease—KIT—thymus cancer	9.13e-06	0.000136	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—TP53—thymus cancer	9.09e-06	0.000135	CbGpPWpGaD
Vandetanib—FYN—Immune System—CD4—thymus cancer	9.09e-06	0.000135	CbGpPWpGaD
Vandetanib—LYN—Developmental Biology—AKT1—thymus cancer	8.95e-06	0.000133	CbGpPWpGaD
Vandetanib—ABL1—Developmental Biology—AKT1—thymus cancer	8.91e-06	0.000132	CbGpPWpGaD
Vandetanib—IRAK4—Immune System—AKT1—thymus cancer	8.82e-06	0.000131	CbGpPWpGaD
Vandetanib—FYN—Developmental Biology—AKT1—thymus cancer	8.81e-06	0.000131	CbGpPWpGaD
Vandetanib—LYN—Hemostasis—AKT1—thymus cancer	8.78e-06	0.00013	CbGpPWpGaD
Vandetanib—SRC—Immune System—KIT—thymus cancer	8.76e-06	0.00013	CbGpPWpGaD
Vandetanib—ABL1—Hemostasis—AKT1—thymus cancer	8.74e-06	0.00013	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—CD4—thymus cancer	8.7e-06	0.000129	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—IL2—thymus cancer	8.7e-06	0.000129	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—IL2—thymus cancer	8.67e-06	0.000129	CbGpPWpGaD
Vandetanib—FYN—Hemostasis—AKT1—thymus cancer	8.65e-06	0.000128	CbGpPWpGaD
Vandetanib—LCK—Hemostasis—TP53—thymus cancer	8.52e-06	0.000127	CbGpPWpGaD
Vandetanib—LYN—Immune System—IL2—thymus cancer	8.49e-06	0.000126	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—IL2—thymus cancer	8.48e-06	0.000126	CbGpPWpGaD
Vandetanib—ABL1—Immune System—IL2—thymus cancer	8.45e-06	0.000126	CbGpPWpGaD
Vandetanib—FYN—Disease—CD4—thymus cancer	8.39e-06	0.000125	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—IL2—thymus cancer	8.39e-06	0.000125	CbGpPWpGaD
Vandetanib—FYN—Immune System—IL2—thymus cancer	8.36e-06	0.000124	CbGpPWpGaD
Vandetanib—ALB—Platelet activation, signaling and aggregation—AKT1—thymus cancer	8.35e-06	0.000124	CbGpPWpGaD
Vandetanib—SRC—Disease—KIT—thymus cancer	8.08e-06	0.00012	CbGpPWpGaD
Vandetanib—PDGFRB—Innate Immune System—AKT1—thymus cancer	8.07e-06	0.00012	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—AKT1—thymus cancer	7.98e-06	0.000119	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—KIT—thymus cancer	7.97e-06	0.000118	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—IL2—thymus cancer	7.93e-06	0.000118	CbGpPWpGaD
Vandetanib—LYN—Innate Immune System—AKT1—thymus cancer	7.91e-06	0.000117	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—IL2—thymus cancer	7.9e-06	0.000117	CbGpPWpGaD
Vandetanib—ABL1—Innate Immune System—AKT1—thymus cancer	7.87e-06	0.000117	CbGpPWpGaD
Vandetanib—EGFR—Immune System—CD4—thymus cancer	7.85e-06	0.000117	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—KIT—thymus cancer	7.8e-06	0.000116	CbGpPWpGaD
Vandetanib—FYN—Innate Immune System—AKT1—thymus cancer	7.78e-06	0.000116	CbGpPWpGaD
Vandetanib—PDGFRB—Adaptive Immune System—AKT1—thymus cancer	7.75e-06	0.000115	CbGpPWpGaD
Vandetanib—ABCC1—Disease—CD4—thymus cancer	7.69e-06	0.000114	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—KIT—thymus cancer	7.68e-06	0.000114	CbGpPWpGaD
Vandetanib—BLK—Immune System—AKT1—thymus cancer	7.68e-06	0.000114	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—AKT1—thymus cancer	7.68e-06	0.000114	CbGpPWpGaD
Vandetanib—FGR—Immune System—AKT1—thymus cancer	7.65e-06	0.000114	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—IL2—thymus cancer	7.62e-06	0.000113	CbGpPWpGaD
Vandetanib—EGFR—Developmental Biology—AKT1—thymus cancer	7.61e-06	0.000113	CbGpPWpGaD
Vandetanib—LYN—Adaptive Immune System—AKT1—thymus cancer	7.59e-06	0.000113	CbGpPWpGaD
Vandetanib—LCK—Immune System—CD4—thymus cancer	7.56e-06	0.000112	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—TP53—thymus cancer	7.55e-06	0.000112	CbGpPWpGaD
Vandetanib—FYN—Adaptive Immune System—AKT1—thymus cancer	7.47e-06	0.000111	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—IL2—thymus cancer	7.36e-06	0.000109	CbGpPWpGaD
Vandetanib—EGFR—Disease—CD4—thymus cancer	7.25e-06	0.000108	CbGpPWpGaD
Vandetanib—EGFR—Immune System—IL2—thymus cancer	7.22e-06	0.000107	CbGpPWpGaD
Vandetanib—LCK—Hemostasis—AKT1—thymus cancer	7.2e-06	0.000107	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—AKT1—thymus cancer	7.03e-06	0.000104	CbGpPWpGaD
Vandetanib—LCK—Disease—CD4—thymus cancer	6.98e-06	0.000104	CbGpPWpGaD
Vandetanib—LCK—Immune System—IL2—thymus cancer	6.96e-06	0.000103	CbGpPWpGaD
Vandetanib—FMO3—Metabolism—AKT1—thymus cancer	6.92e-06	0.000103	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—AKT1—thymus cancer	6.72e-06	9.99e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—CD4—thymus cancer	6.7e-06	9.95e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—KIT—thymus cancer	6.64e-06	9.86e-05	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—AKT1—thymus cancer	6.5e-06	9.65e-05	CbGpPWpGaD
Vandetanib—ERBB3—Disease—AKT1—thymus cancer	6.5e-06	9.65e-05	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—AKT1—thymus cancer	6.48e-06	9.63e-05	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—AKT1—thymus cancer	6.46e-06	9.59e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—KIT—thymus cancer	6.39e-06	9.5e-05	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—AKT1—thymus cancer	6.37e-06	9.46e-05	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—AKT1—thymus cancer	6.22e-06	9.24e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—CD4—thymus cancer	6.18e-06	9.18e-05	CbGpPWpGaD
Vandetanib—YES1—Immune System—AKT1—thymus cancer	6.18e-06	9.17e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—IL2—thymus cancer	6.16e-06	9.15e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—TP53—thymus cancer	6.11e-06	9.08e-05	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—AKT1—thymus cancer	5.74e-06	8.52e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—KIT—thymus cancer	5.66e-06	8.41e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—IL2—thymus cancer	5.61e-06	8.33e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—TP53—thymus cancer	5.59e-06	8.3e-05	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—AKT1—thymus cancer	5.51e-06	8.18e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—IL2—thymus cancer	5.49e-06	8.15e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—TP53—thymus cancer	5.45e-06	8.09e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—IL2—thymus cancer	5.41e-06	8.03e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—TP53—thymus cancer	5.39e-06	8e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—AKT1—thymus cancer	5.16e-06	7.66e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—TP53—thymus cancer	5.1e-06	7.57e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—TP53—thymus cancer	4.89e-06	7.27e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—TP53—thymus cancer	4.73e-06	7.02e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—AKT1—thymus cancer	4.72e-06	7.01e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—AKT1—thymus cancer	4.7e-06	6.99e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IL2—thymus cancer	4.67e-06	6.94e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—AKT1—thymus cancer	4.6e-06	6.84e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—AKT1—thymus cancer	4.6e-06	6.83e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—AKT1—thymus cancer	4.58e-06	6.81e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—AKT1—thymus cancer	4.55e-06	6.76e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—AKT1—thymus cancer	4.53e-06	6.73e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IL2—thymus cancer	4.5e-06	6.68e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—AKT1—thymus cancer	4.34e-06	6.45e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—AKT1—thymus cancer	4.3e-06	6.39e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—AKT1—thymus cancer	4.29e-06	6.37e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—AKT1—thymus cancer	4.19e-06	6.22e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—AKT1—thymus cancer	4.13e-06	6.14e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—AKT1—thymus cancer	3.99e-06	5.93e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IL2—thymus cancer	3.98e-06	5.92e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—AKT1—thymus cancer	3.92e-06	5.82e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—AKT1—thymus cancer	3.84e-06	5.7e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—AKT1—thymus cancer	3.77e-06	5.61e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—AKT1—thymus cancer	3.62e-06	5.37e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—TP53—thymus cancer	3.6e-06	5.35e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—TP53—thymus cancer	3.53e-06	5.24e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—AKT1—thymus cancer	3.48e-06	5.18e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—TP53—thymus cancer	3.47e-06	5.16e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—AKT1—thymus cancer	3.34e-06	4.96e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—AKT1—thymus cancer	3.21e-06	4.77e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—AKT1—thymus cancer	3.08e-06	4.58e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—AKT1—thymus cancer	3.04e-06	4.52e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TP53—thymus cancer	3e-06	4.45e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—AKT1—thymus cancer	2.98e-06	4.42e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—AKT1—thymus cancer	2.93e-06	4.35e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TP53—thymus cancer	2.89e-06	4.29e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—AKT1—thymus cancer	2.83e-06	4.2e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TP53—thymus cancer	2.56e-06	3.8e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—AKT1—thymus cancer	2.53e-06	3.76e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—AKT1—thymus cancer	2.44e-06	3.62e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—AKT1—thymus cancer	2.16e-06	3.21e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—AKT1—thymus cancer	1.74e-06	2.59e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—AKT1—thymus cancer	9.42e-07	1.4e-05	CbGpPWpGaD
